Reversion of Somatic Mutations of the Respiratory Syncytial Virus–Specific Human Monoclonal Antibody Fab19 Reveal a Direct Relationship between Association Rate and Neutralizing Potency-Reference-Cited by-同舟云学术

Reversion of Somatic Mutations of the Respiratory Syncytial Virus–Specific Human Monoclonal Antibody Fab19 Reveal a Direct Relationship between Association Rate and Neutralizing Potency

Published:2013-03-01 Issue:7 Volume:190 Page:3732-3739
ISSN:0022-1767
Container-title:The Journal of Immunology
language:en
Short-container-title:J.I.

Author:

Bates John T.,Keefer Christopher J.,Utley Thomas J.,Correia Bruno E.,Schief William R.,Crowe James E.

Publisher

The American Association of Immunologists

Subject

Immunology,Immunology and Allergy

Reference52 articles.

1. Respiratory Syncytial Virus—Viral Biology and the Host Response

2. Basic epidemiology and immunopathology of RSV in children

3. Respiratory syncytial virus infection: immune response, immunopathogenesis, and treatment.;Domachowske;Clin. Microbiol. Rev.,1999

4. Palivizumab, a Humanized Respiratory Syncytial Virus Monoclonal Antibody, Reduces Hospitalization From Respiratory Syncytial Virus Infection in High-risk Infants

5. Prevention of respiratory syncytial virus infections in high-risk infantsby monoclonal antibody (palivizumab)

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Description of a non-competitive ELISA based on time course analysis of ligand binding at saturation, and a direct method for calculating the affinity of monoclonal antibodies;Journal of Immunological Methods;2024-11

2. Minimal Determinants for Lifelong Antiviral Antibody Responses in Mice from a Single Exposure to Virus-like Immunogens at Low Doses;Vaccines;2024-04-11

3. Somatic hypermutation introduces bystander mutations that prepare SARS-CoV-2 antibodies for emerging variants;Immunity;2023-12

4. Dissecting the impact of somatic hypermutation on SARS-CoV-2 neutralization and viral escape;2023-05-09

5. Minimal determinants for lifelong antiviral antibody responses from a single exposure to virus-like immunogens at low doses;2023-02-21